A blood test for antibodies produced in the immune system may potentially be used in the future to diagnose Alzheimer’s disease in its early stage.
The U.S. Department of Health and Human Services has announced it will provide $750 million to fund new prevention and public health programs, made available through the new healthcare law’s Prevention and Public Health Fund.
Researchers from the Royal Women’s Hospital and Monash University in Melbourne, Australia, are testing immune modulation therapy to treat ovarian cancer.
French investigators found that infusion of human serum albumin formulated at a 4% concentration significantly improved survival time in Swiss mice injected with lipopolysaccharide endotoxin, while 20% human albumin and normal saline provided no protective benefit.
An observational, multicenter cohort study found that in patients evaluated during the flu season, community-acquired pneumonia was less severe in those who had received flu vaccine than in those who had not
The Cancer Research Institute has launched the Cancer Vaccine Acceleration Fund to speed the clinical development of therapeutic cancer vaccines and other immune system-based therapies.
The Ritedose Corp. is voluntarily recalling its 0.083% Albuterol Sulfate Inhalation Solution, 3 mL in 25-, 30- and60-unit dose vials.
Scientists at the Health Protection Agency in England have made a breakthrough in determining the causes of encephalitis.
Scientists at the University of California, San Diego School of Medicine have created the first “lipidome” of human plasma, identifying and quantifying almost 600 distinct fat species in human blood.
A recent study has found that people infected with H1N1 swine flu produce antibodies that are protective against a variety of flu strains, which may help scientists eventually develop a universal vaccine.
A new cancer test is sensitive enough to spot a single cancer cell among a billion healthy cells, which may offer a better way to screen for the disease than methods currently used.
New findings from the VWD International Prophylaxis Study showed that prophylactic von Willebrand factor replacement therapy significantly reduces the median number of bleeding episodes
in 39 subjects severely affected with von Willebrand disease.